1
|
Spindler L, Etienney I, Abramowitz L, de Parades V, Pigot F, Siproudhis L, Adam J, Balzano V, Bouchard D, Bouta N, Bucau M, Carlo A, Chanal J, Charpentier C, Clifford G, Draullette M, Fathallah N, Ferré V, Fléjou JF, Fouéré S, Higuero T, Kassouri L, Kurt S, Laurain A, Leclerc E, Lepiller Q, Lesage AC, Mège D, Ménard A, Merle P, Mortreux P, Noël C, Péré H, Prétet JL, Roland D, Staumont G, Tracanelli L, Vuitton L, Wylomanski S, Zaegel-Faucher O. Screening for precancerous anal lesions linked to human papillomaviruses: French recommendations for clinical practice. Tech Coloproctol 2024; 28:23. [PMID: 38198036 PMCID: PMC10781838 DOI: 10.1007/s10151-023-02899-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Accepted: 12/01/2023] [Indexed: 01/11/2024]
Abstract
In France, about 2000 new cases of anal cancer are diagnosed annually. Squamous cell carcinoma is the most common histological type, mostly occurring secondary to persistent HPV16 infection. Invasive cancer is preceded by precancerous lesions. In addition to patients with a personal history of precancerous lesions and anal cancer, three groups are at very high risk of anal cancer: (i) men who have sex with men and are living with HIV, (ii) women with a history of high-grade squamous intraepithelial lesions (HSILs) or vulvar HPV cancer, and (iii) women who received a solid organ transplant more than 10 years ago. The purpose of screening is to detect HSILs so that they can be treated, thereby reducing the risk of progression to cancer. All patients with symptoms should undergo a proctological examination including standard anoscopy. For asymptomatic patients at risk, an initial HPV16 test makes it possible to target patients at risk of HSILs likely to progress to cancer. Anal cytology is a sensitive test for HSIL detection. Its sensitivity is greater than 80% and exceeds that of proctological examination with standard anoscopy. It is indicated in the event of a positive HPV16 test. In the presence of cytological abnormalities and/or lesions and a suspicion of dysplasia on clinical examination, high-resolution anoscopy is indicated. Performance is superior to that of proctological examination with standard anoscopy. However, this technique is not widely available, which limits its use. If high-resolution anoscopy is not possible, screening by a standard proctological examination is an alternative. There is a need to develop high-resolution anoscopy and triage tests and to evaluate screening strategies.
Collapse
Affiliation(s)
- L Spindler
- Service de Proctologie, Groupe Hospitalier Paris Saint-Joseph, Paris, France.
| | - I Etienney
- Service de Proctologie, Hôpital Diaconesses-Croix Saint Simon, Paris, France
| | - L Abramowitz
- Service de Proctologie, APHP Hôpital Bichat-Claude Bernard and Ramsay GDS Clinique Blomet, Paris, France
| | - V de Parades
- Service de Proctologie, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - F Pigot
- Service de Proctologie, Hôpital Bagatelle, Talence, France
| | - L Siproudhis
- Service d'Hépato-Gastroentérologie, CHU Pontchaillou, Rennes, France
| | - J Adam
- Service d'Anatomopathologie, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - V Balzano
- Service de Gastroentérologie et Oncologie Digestive, CHU Tours, Tours, France
| | - D Bouchard
- Service de Proctologie, Hôpital Bagatelle, Talence, France
| | - N Bouta
- Service d'Hépato-Gastroentérologie et de Proctologie, Clinique La Croix du Sud, Quint-Fonsegrives, France
| | - M Bucau
- Service d'Anatomopathologie, AP-HP Hôpital Bichat-Claude Bernard, Paris, France
| | - A Carlo
- Service d'Hépato-Gastroentérologie, CHU Pontchaillou, Rennes, France
| | - J Chanal
- Service de Dermatologie, AP-HP, Hôpital Tarnier, Paris, France
| | - C Charpentier
- Département de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, INSERM, IAME, Université de Paris, Paris, France
| | - G Clifford
- Early Detection, Prevention, and Infections Branch, International Agency for Research On Cancer, Lyon, France
| | - M Draullette
- Service d'Hépato-Gastroentérologie et Assistance Nutritive, AP-HP, Hôpital Beaujon, Clichy, France
| | - N Fathallah
- Service de Proctologie, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - V Ferré
- Département de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, INSERM, IAME, Université de Paris, Paris, France
| | - J-F Fléjou
- Service d'Anatomopathologie, Cerbapath, Paris, France
| | - S Fouéré
- Service de Dermatologie, AP-HP, Hôpital Saint-Louis, Université de Paris, Paris, France
- Centre des Maladies Sexuellement Transmises, AP-HP, Hôpital Saint-Louis, Paris, France
| | - T Higuero
- Gastro-entérologue, proctologue medico-chirurgical, Beausoleil, France
| | - L Kassouri
- Service de Proctologie, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - S Kurt
- Service de Proctologie, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - A Laurain
- Service de Proctologie, APHP Hôpital Bichat-Claude Bernard and Ramsay GDS Clinique Blomet, Paris, France
| | - E Leclerc
- Service d'Hépato-Gastroentérologie, CHU Clermont-Ferrand, Inserm, 3iHP, Université Clermont Auvergne, Clermont-Ferrand, France
| | - Q Lepiller
- Laboratoire de Virologie, CHU de Besançon, Besançon, France
| | - A-C Lesage
- Service de Proctologie, Hôpital Diaconesses-Croix Saint Simon, Paris, France
| | - D Mège
- Service de Chirurgie Digestive, Université d'Aix Marseille, AP-HM, Hôpital de la Timone, Marseille, France
| | - A Ménard
- Institut Hospitalo-Universitaire Méditerranée Infection, AP-HM, Hôpital Nord, Université d'Aix Marseille, Marseille, France
| | - P Merle
- Service d'Hépato-Gastroentérologie et de Proctologie, Clinique La Croix du Sud, Quint-Fonsegrives, France
| | - P Mortreux
- Service de Gastroentérologie, Centre Hospitalier de Bethune Beuvry, Beuvry, France
| | - C Noël
- Service d'Hépato-Gastroentérologie, CHU de Brest, Brest, France
| | - H Péré
- Laboratoire de Virologie, Service de Microbiologie, AP-HP, Hôpital Européen Georges Pompidou, Paris, France
- Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordelier, INSERM, Université de Paris, Sorbonne Université, Paris, France
| | - J-L Prétet
- EA3181, Université de Franche-Comté, LabEx LipSTIC ANR-11-LABX-0021, Besançon, France
- Centre National de Référence Papillomavirus, CHU de Besançon, Besançon, France
| | - D Roland
- Service de Proctologie, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - G Staumont
- Service d'Hépato-Gastroentérologie et de Proctologie, Clinique La Croix du Sud, Quint-Fonsegrives, France
| | - L Tracanelli
- Service de Proctologie, Hôpital Bagatelle, Talence, France
| | - L Vuitton
- Service de Gastroentérologie, CHU de Besançon, Université de Bourgogne Franche-Comté, Besançon, France
| | - S Wylomanski
- Service de Gynécologie, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - O Zaegel-Faucher
- Service d'Immuno-Hématologie Clinique, AP-HM, CHU Sainte-Marguerite, Marseille, France
| |
Collapse
|
2
|
Baraquin A, Pépin L, Floerchinger P, Lepiller Q, Prétet JL. [New recommendations for cervical cancer screening in France]. Ann Pharm Fr 2023; 81:202-209. [PMID: 36150499 DOI: 10.1016/j.pharma.2022.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 08/30/2022] [Accepted: 09/16/2022] [Indexed: 10/14/2022]
Abstract
In France, recent advances in cervical cancer screening include an organized cervical cancer-screening program and the introduction of HPV testing as a first-line test for women aged 30-65 years. The HPV test, performed on a cervical smear taken by a health professional, could also be performed on a vaginal self-sample in certain indications. The detection kits used to test for HPV should target high-risk HPV, be validated for screening and meet the performance requirements for this indication. Although no longer used as a first-line test in women aged 30-65 years, cytological examination of cervical cells remains important, particularly in the triage of HPV positive women. The interest of other biological techniques, such as HPV genotyping, viral load, cellular expression of p16/Ki-67 proteins and the methylation of cellular or viral genes, still needs to be clarified, but they could help to refine the triage strategy of HPV-positive women and limit the need for colposcopy and unnecessary stress for patients.
Collapse
Affiliation(s)
- A Baraquin
- Centre national de référence papillomavirus, CHU de Besançon, boulevard Alexandre-Fleming, 25000 Besançon, France
| | - L Pépin
- Centre national de référence papillomavirus, CHU de Besançon, boulevard Alexandre-Fleming, 25000 Besançon, France; Laboratoire de virologie, CHU de Besançon, boulevard Alexandre-Fleming, 25000 Besançon, France
| | - P Floerchinger
- Service de gynécologie obstétrique, CHU de Besançon, boulevard Alexandre-Fleming, 25000 Besançon, France
| | - Q Lepiller
- Centre national de référence papillomavirus, CHU de Besançon, boulevard Alexandre-Fleming, 25000 Besançon, France; Laboratoire de virologie, CHU de Besançon, boulevard Alexandre-Fleming, 25000 Besançon, France; EA3181 carcinogenèse associée aux HPV, UFR sciences de la santé, université Bourgogne Franche-Comté, rue Ambroise-Paré, 25000 Besançon, France
| | - J-L Prétet
- Centre national de référence papillomavirus, CHU de Besançon, boulevard Alexandre-Fleming, 25000 Besançon, France; EA3181 carcinogenèse associée aux HPV, UFR sciences de la santé, université Bourgogne Franche-Comté, rue Ambroise-Paré, 25000 Besançon, France.
| |
Collapse
|
3
|
Puget L, Berceanu A, Node J, Coaquette A, Overs A, Herbein G, Prétet JL, Daguindau E, Lepiller Q. Human cytomegalovirus-viruria in hematopoietic stem cell transplant recipients: Context and impact. Infect Dis Now 2023; 53:104651. [PMID: 36702306 DOI: 10.1016/j.idnow.2023.104651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Revised: 01/05/2023] [Accepted: 01/15/2023] [Indexed: 01/24/2023]
Abstract
BACKGROUND Episodes of CMV-viruria have been reported in hematopoietic stem cell transplant (HSCT) recipients, but their context of occurrence, pathophysiology, and clinical significance remain misunderstood. METHODS Uurine samples from 517 recipients were collected. Clinical features of recipients with or without episodes of CMV-viruria were retrospectively compared. RESULTS CMV-viruria was detected in 15.5 % of cases. Age, sex, type of transplantation, HLA-matching, conditioning regimen, and immunosuppressive therapies did not differ between patients with and without CMV-viruria. CMV-seropositive status (R + ) was more frequent among CMV-viruric recipients. Cumulated mortality did not differ between the two groups but graft-versus-host diseases occurred more frequently among CMV-viruric patients (p = 0.04). No reduction of the estimated glomerular filtration rates was observed in CMV-viruric recipients. CONCLUSIONS CMV-viruria primarily occurs in CMV-seropositive recipients and is not related to the degree of immunosuppression. We suggest that CMV-viruria is primarily related to the inability of the graft immune system to contain CMV-replication in R + patients. CMV-viruria is not associated with increased mortality or renal dysfunction.
Collapse
Affiliation(s)
- L Puget
- Laboratoire de Virologie, CHU Besançon, France
| | - A Berceanu
- Service d'Hématologie, CHU Besançon, France
| | - J Node
- Laboratoire de Virologie, CHU Besançon, France
| | - A Coaquette
- Laboratoire de Virologie, CHU Besançon, France
| | - A Overs
- Laboratoire de Virologie, CHU Besançon, France
| | - G Herbein
- Laboratoire de Virologie, CHU Besançon, France; EA4266, Université Bourgogne Franche-Comté, France
| | - J-L Prétet
- Laboratoire de Biologie Cellulaire et Moléculaire, CHU Besançon, France; EA3181, Université Bourgogne Franche-Comté, France
| | - E Daguindau
- Service d'Hématologie, CHU Besançon, France; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Q Lepiller
- Laboratoire de Virologie, CHU Besançon, France; EA3181, Université Bourgogne Franche-Comté, France.
| |
Collapse
|
4
|
Marty-Quinternet S, Puget L, Debernardi A, Aubry R, Magy-Bertrand N, Prétet JL, Chirouze C, Bouiller K, Lepiller Q. Electrostatic wipes as simple and reliable methods for influenza virus airborne detection. J Hosp Infect 2020; 108:15-18. [PMID: 33197489 DOI: 10.1016/j.jhin.2020.10.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Revised: 10/03/2020] [Accepted: 10/18/2020] [Indexed: 11/18/2022]
Abstract
The performance of an in-house protocol for virus detection on commercialized electrostatic wipes (EWs) was assessed experimentally by impregnating them with suspensions of cytomegalovirus, adenovirus, and influenza virus, and by determining the recovery efficiency, repeatability, and detection limit of the protocol. The protocol was sensitive enough to detect 4 log10 gene copies of virus. At room temperature, influenza RNA was stable on EWs for at least four days. When EWs were placed high in 32 influenza-infected patients' rooms, influenza RNA was detectable in 75% (N = 24) of EWs, suggesting that EWs are simple and reliable methods for influenza virus airborne detection.
Collapse
Affiliation(s)
| | - L Puget
- Laboratoire de Virologie, CHU, Besançon, France
| | - A Debernardi
- EA3181, Université Bourgogne Franche-Comté, France
| | - R Aubry
- Service de gériatrie, CHU, Besançon, France
| | | | - J L Prétet
- EA3181, Université Bourgogne Franche-Comté, France; Laboratoire de biologie cellulaire, CHU, Besançon, France
| | - C Chirouze
- Service de maladies infectieuses, CHU, Besançon, France
| | - K Bouiller
- Service de maladies infectieuses, CHU, Besançon, France
| | - Q Lepiller
- Laboratoire de Virologie, CHU, Besançon, France; EA3181, Université Bourgogne Franche-Comté, France.
| |
Collapse
|
5
|
Bretagne CH, Jooste V, Guenat D, Riethmuller D, Bouvier AM, Bedgedjian I, Prétet JL, Valmary-Degano S, Mougin C. Prevalence and distribution of HPV genotypes and cervical-associated lesions in sexually active young French women following HPV vaccine. J Gynecol Obstet Hum Reprod 2018; 47:525-531. [PMID: 29807205 DOI: 10.1016/j.jogoh.2018.05.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 05/21/2018] [Accepted: 05/23/2018] [Indexed: 01/22/2023]
Abstract
BACKGROUND Despite the availability of safe and effective HPV vaccines in France, more than 80% of girls remain unvaccinated. SETTING A regional university hospital referral center in France. OBJECTIVE To estimate the overall prevalence and distribution of HPV in vaccinated, sexually active young French women who were screened for cervical cancer by cytology and HPV testing. METHODS High-risk HPV (HR-HPV) prevalence, genotype-specific prevalence and extent of multiple infections were assessed in 125 cervical samples from females with available vaccine data using hc2 assay and INNO-LiPA assay. HPV status was analyzed in accordance with cytological data. RESULTS In our series, mean age was 23 years, overall prevalence of HR-HPV was 52% and was correlated with the lesion grade. The diversity of HPV genotypes was broad. Single HR-HPV infections were identified in 11%, 21% and 47% of women with NILM, ASC-US/-H and LSIL respectively. Multiple infections with HR-HPV were detected in 28% of the specimens. Only 24.5% of women with NILM presented infections with 2 genotypes or more, vs 28% of women with ASC-US/-H and 35% of women with LSIL. The overall prevalence of genotypes covered by the quadrivalent vaccine was low (5.9%); with 4.2%, 0%, 0.8% and 0.8% for HPV 16, HPV 18, HPV 6 and HPV 11 respectively. CONCLUSION Among HPV-vaccinated young women, HR-HPV are detected at a high rate, and an association with the grade of cytological abnormalities was observed. However, HPV 16 and 18, both targeted by the vaccines, are remarkably rare among young French women since program implementation.
Collapse
Affiliation(s)
- C H Bretagne
- Service d'Anatomie et cytologie pathologiques, CHU Besançon, Bd Fleming, 25000 Besançon, France.
| | - V Jooste
- Registre Bourguignon des Cancers Digestifs, Hôpital Universitaire Dijon-Bourgogne, 21000 Dijon, France; INSERM, U1231, EPICAD Team, Université Bourgogne-Franche-Comté, 21000 Dijon, France.
| | - D Guenat
- EA 3181, UFR SMP, Université Bourgogne Franche-Comté, LabEx LipSTIC ANR-11-LABX-0021, rue Ambroise Paré, 25000 Besançon, France; Centre National de Référence Papillomavirus, CHU Besançon, Bd Fleming, 25000 Besançon, France.
| | - D Riethmuller
- EA 3181, UFR SMP, Université Bourgogne Franche-Comté, LabEx LipSTIC ANR-11-LABX-0021, rue Ambroise Paré, 25000 Besançon, France; Service de gynécologie obstétrique, CHU Besançon, Bd Fleming, 25000 Besançon, France.
| | - A M Bouvier
- Registre Bourguignon des Cancers Digestifs, Hôpital Universitaire Dijon-Bourgogne, 21000 Dijon, France; INSERM, U1231, EPICAD Team, Université Bourgogne-Franche-Comté, 21000 Dijon, France.
| | - I Bedgedjian
- Service d'Anatomie et cytologie pathologiques, CHU Besançon, Bd Fleming, 25000 Besançon, France.
| | - J L Prétet
- EA 3181, UFR SMP, Université Bourgogne Franche-Comté, LabEx LipSTIC ANR-11-LABX-0021, rue Ambroise Paré, 25000 Besançon, France; Centre National de Référence Papillomavirus, CHU Besançon, Bd Fleming, 25000 Besançon, France.
| | - S Valmary-Degano
- Service d'Anatomie et cytologie pathologiques, CHU Besançon, Bd Fleming, 25000 Besançon, France; EA 3181, UFR SMP, Université Bourgogne Franche-Comté, LabEx LipSTIC ANR-11-LABX-0021, rue Ambroise Paré, 25000 Besançon, France.
| | - C Mougin
- EA 3181, UFR SMP, Université Bourgogne Franche-Comté, LabEx LipSTIC ANR-11-LABX-0021, rue Ambroise Paré, 25000 Besançon, France; Centre National de Référence Papillomavirus, CHU Besançon, Bd Fleming, 25000 Besançon, France.
| |
Collapse
|
6
|
Guenat D, Riethmuller D, Ramanah R, Morel A, Aubin F, Mougin C, Prétet JL. [Molecular diagnosis of human papillomaviruses (HPV): What test(s) in clinical practice?]. J Gynecol Obstet Hum Reprod 2016; 45:1009-1019. [PMID: 27771203 DOI: 10.1016/j.jgyn.2016.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2016] [Revised: 09/02/2016] [Accepted: 09/07/2016] [Indexed: 06/06/2023]
Abstract
Prescription of an HPV test in practice will enable the clinician to optimize the monitoring and the management of patients, especially in the context of cervical cancer screening. Numerous HPV tests are available that present different analytical and clinical sensitivity and specificity. International recommendations on clinical performance of HPV tests used for cervical cancer screening have been published by a group of experts, and tests that meet these performance criteria should be used. Apart from the HPV detection kit, the whole circuit from sampling to report of the results must be considered. This implies that the pre-analytical (sampling, quality of sample collection medium, storage condition and sample transportation…) and post-analytical steps (quality of result reporting, providing expert advices…) are also standardized. For this purpose, medical-biology laboratories are subjected to a COFRAC certification, as defined by the international standard ISO 15189 providing quality criteria for any clinical laboratory test and HPV test in particular.
Collapse
Affiliation(s)
- D Guenat
- Université Franche-Comte, COMUE UBFC, 25000 Besançon, France; CHRU de Besançon, 25000 Besançon, France; EA 3181, LabEx LipSTIC ANR-11-LABX-0021, FED4234, 25000 Besançon, France
| | - D Riethmuller
- Université Franche-Comte, COMUE UBFC, 25000 Besançon, France; CHRU de Besançon, 25000 Besançon, France; EA 3181, LabEx LipSTIC ANR-11-LABX-0021, FED4234, 25000 Besançon, France
| | - R Ramanah
- Université Franche-Comte, COMUE UBFC, 25000 Besançon, France; CHRU de Besançon, 25000 Besançon, France; EA 3181, LabEx LipSTIC ANR-11-LABX-0021, FED4234, 25000 Besançon, France
| | - A Morel
- Université Franche-Comte, COMUE UBFC, 25000 Besançon, France; EA 3181, LabEx LipSTIC ANR-11-LABX-0021, FED4234, 25000 Besançon, France
| | - F Aubin
- Université Franche-Comte, COMUE UBFC, 25000 Besançon, France; CHRU de Besançon, 25000 Besançon, France; EA 3181, LabEx LipSTIC ANR-11-LABX-0021, FED4234, 25000 Besançon, France
| | - C Mougin
- Université Franche-Comte, COMUE UBFC, 25000 Besançon, France; CHRU de Besançon, 25000 Besançon, France; EA 3181, LabEx LipSTIC ANR-11-LABX-0021, FED4234, 25000 Besançon, France
| | - J-L Prétet
- Université Franche-Comte, COMUE UBFC, 25000 Besançon, France; CHRU de Besançon, 25000 Besançon, France; EA 3181, LabEx LipSTIC ANR-11-LABX-0021, FED4234, 25000 Besançon, France; Inserm CIC 1431, 25000 Besançon, France.
| |
Collapse
|
7
|
Bouvret P, Mougin C, Prétet JL, Meurisse A, Bonnetain F, Fiteni F. [Practices and attitudes regarding HPV vaccination among general practitioners from Besançon]. ACTA ACUST UNITED AC 2016; 45:972-978. [PMID: 26780841 DOI: 10.1016/j.jgyn.2015.12.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Revised: 11/20/2015] [Accepted: 12/18/2015] [Indexed: 10/22/2022]
Abstract
OBJECTIVES To assess opinions, practices and difficulties of general practitioners (GP) of Besançon concerning human papillomavirus (HPV) vaccination. MATERIALS AND METHODS A survey among the 140 GP of Besançon, France, was conducted in 2015. RESULTS A percentage of 77.1 reported being favourable to HPV vaccination and 72.9% practices HPV vaccination. The 2 main concerns about HPV vaccination for GP are the fear of side effects (for 40.6% of GP) and the doubt on efficacy. According to GP, the hepatitis B vaccination controversy, the fear of side effects, the limited clinical efficacy experience and the lack of confidence in health authorities are concerns about HPV vaccination for 77.1%, 76%, 74% and 49% of patients, respectively. CONCLUSION Courses for GP on HPV vaccination must be pursued and reinforced. A school-based program could be developed to facilitate communication between GP and patients to improve HPV vaccination coverage.
Collapse
Affiliation(s)
- P Bouvret
- Unité de méthodologie et qualité de vie en cancérologie, centre hospitalier universitaire de Besançon, 25000 Besançon, France
| | - C Mougin
- Université Franche-Comté, COMUE uB-FC, 25000 Besançon, France; CHRU de Besançon, 25000 Besançon, France; EA 3181, LabEx LipSTIC ANR-11-LABX-0021, FED4234, Inserm CIC-1431, 25000 Besançon, France
| | - J-L Prétet
- Université Franche-Comté, COMUE uB-FC, 25000 Besançon, France; CHRU de Besançon, 25000 Besançon, France; EA 3181, LabEx LipSTIC ANR-11-LABX-0021, FED4234, Inserm CIC-1431, 25000 Besançon, France
| | - A Meurisse
- Unité de méthodologie et qualité de vie en cancérologie, centre hospitalier universitaire de Besançon, 25000 Besançon, France
| | - F Bonnetain
- Unité de méthodologie et qualité de vie en cancérologie, centre hospitalier universitaire de Besançon, 25000 Besançon, France; EA 3181, LabEx LipSTIC ANR-11-LABX-0021, FED4234, Inserm CIC-1431, 25000 Besançon, France
| | - F Fiteni
- Unité de méthodologie et qualité de vie en cancérologie, centre hospitalier universitaire de Besançon, 25000 Besançon, France; Service d'oncologie médicale, centre hospitalier universitaire de Besançon, 3, boulevard Fleming, 25000 Besançon, France.
| |
Collapse
|
8
|
Martin M, Mougin C, Prétet JL, Gil H, Meaux-Ruault N, Puzenat E, Ramanah R, Aubin F, Touzé A, Coursaget P, Jacquin E, Magy-Bertrand N. Screening of human papillomavirus infection in women with systemic sclerosis. Clin Exp Rheumatol 2014; 32:S-145-8. [PMID: 25151849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2014] [Accepted: 04/14/2014] [Indexed: 06/03/2023]
Abstract
OBJECTIVES High risk human papilloma-viruses (HR HPV) are associated with risk of cervical dysplasia and carcinoma. The risk is increased in patients with immune deficiency or auto-immune disease as systemic lupus erythematosus. Currently, no data are available about the human papillomavirus status in women with systemic sclerosis (SSc). METHODS Thirty-one women with SSc were evaluated for cervical HPV infection and dysplasia, and compared to fifty age-matched control. Cervical swabs were tested by the INNO-LiPA assay®. Serum antibodies against HPV 16 and 18 were assessed using enzyme-linked immunosorbent assay in the SSc group. RESULTS The overall HPV frequency was comparable between SSc and controls (32% vs. 38%), as well as the HR HPV frequency (28% vs. 34%), but infection by ≥2 HPV was two times more frequent in the SSc group (50% vs. 26% of the HPV positive samples). The most prevalent genotype was 52 in the SSc group (12%), and 52/53 in the control group (8% for both). Pap smears were within the normal range. Seropositivity for HPV 16 and 18 was 13% and 6.5%, respectively. A diffuse systemic sclerosis and a younger age at first intercourse were more frequent in cases of overall HPV positivity. Current smoking and a higher number of sexual partners were only observed in cases of seropositivity. CONCLUSIONS This is the first study to evaluate HPV status in women with SSc. HR HPV52 was the most common genotype with a greater multi-HPV infection rate. This result needs to be confirmed in a larger study.
Collapse
Affiliation(s)
- M Martin
- Service de Médecine Interne, CHU Besançon, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Bellaud G, Gheit T, Pugin A, Prétet JL, Tommasino M, Mougin C, Aubin F. Prevalence of human polyomavirus DNA in eyebrow hairs plucked from patients with psoriasis treated with TNF inhibitors. J Eur Acad Dermatol Venereol 2014; 29:1019-21. [PMID: 24597770 DOI: 10.1111/jdv.12439] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- G Bellaud
- Service de Dermatologie, Centre Hospitalier Universitaire, Besançon, France
| | | | | | | | | | | | | |
Collapse
|
10
|
Bellaud G, Gheit T, Pugin A, Prétet JL, Tommasino M, Mougin C, Aubin F. Prevalence of human Papillomavirus DNA in eyebrow hairs plucked from patients with psoriasis treated with TNF inhibitors. J Eur Acad Dermatol Venereol 2013; 28:1816-20. [PMID: 24206262 DOI: 10.1111/jdv.12308] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Accepted: 09/30/2013] [Indexed: 01/25/2023]
Abstract
BACKGROUND Tumour necrosis factor alpha (TNF-α) inhibitors are associated with an increased risk of infections and with a still debatable risk of skin cancer. Furthermore, cutaneous human papillomavirus (HPV) infection may be involved in skin cancer. OBJECTIVES Our primary objective was to assess the HPV DNA prevalence in psoriasis patients treated with TNF inhibitors and the secondary objective was to assess the same parameter before and during treatment. METHODS Plucked eyebrow hairs were collected from 151 consecutive patients with moderate to severe chronic plaque psoriasis, including 48 patients treated with anti-TNF-α agents, 21 patients treated with methotrexate (MTX) and 82 patients with no previous systemic treatment. Among them, 38 patients were subsequently treated with either MTX or anti-TNF-α agents. HPV genotyping was performed using the HPV type-specific E7 PCR bead-based multiplex allowing the detection of 27 genus-α types, 25 genus-β types, 16 genus-γ types and one single genus-μ type. Follow-up provided a total of 972.7 person-months of overall exposure for patients treated with TNF inhibitors and 326.9 person-months for patients treated with MTX. RESULTS Our data confirm the high prevalence of β-HPV infection in healthy skin of psoriasis patients (68.9%), with no significant difference between untreated patients (64.6%), patients treated with MTX (76.2%) and patients treated with anti-TNF-α agents (72.9%). The mean number of different HPV types and the distribution of HPV types were similar in different groups of patients. Moreover, in prospectively treated patients, we did not observe any change in the HPV DNA prevalence in the distribution of HPV types and the number of HPV types after a mean duration of treatment of 332 ± 39.8 days. CONCLUSION Despite the small number of patients in our cohort, our results are quite encouraging in view of the increased use of anti-TNF-α agents in different auto inflammatory immune diseases.
Collapse
Affiliation(s)
- G Bellaud
- Service de Dermatologie, Centre Hospitalier Universitaire, Besançon, France
| | | | | | | | | | | | | |
Collapse
|
11
|
Charlot JF, Nicolier M, Prétet JL, Mougin C. Modulation of p53 transcriptional activity by PRIMA-1 and Pifithrin-alpha on staurosporine-induced apoptosis of wild-type and mutated p53 epithelial cells. Apoptosis 2006; 11:813-27. [PMID: 16554962 DOI: 10.1007/s10495-006-5876-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
We recently argued for a major role of p53 in staurosporine(ST)-induced apoptosis of immortalized epithelial cells, depending on their p53 status. Here, we studied the effects of PRIMA-1 (p53 reactivation and induction of massive apoptosis) and Pifithrin-alpha (p fifty-three inhibitor) in combination with ST to reinforce our previous results by respectively restoring or inhibiting the p53 transcriptional activity in different cell lines.PRIMA-1 does modify neither expression of apoptosis-related proteins nor the percentage of wild-type p53 HeLa and CaSki cells with [symbol: see text]delta psi m and DNA cleavage, whilst it increases by 45% Bax expression and apoptosis of mutated p53 C33A cells. Pifithrin-alpha, does modify neither Bax expression nor apoptosis level of C33A cells, but readily inhibits both [symbol: see text]delta psi m and DNA fragmentation of p53wt cells with decreasing Bax expression. These data support the evidence that PRIMA-1 could be a good candidate, as an anti-cancer drug targeting mutant p53, in order to increase ST efficiency. Moreover, Pifithrin-alpha could be used in combination with ST and PRIMA-1 to prevent side effects of anti-tumor therapies in cells expressing mutant P53.
Collapse
Affiliation(s)
- J F Charlot
- Université de Franche-Comté, UFR Médecine et Pharmacie, EA 3181, IFR 133. 19 rue Ambroise Paré, 25000 Besançon, France
| | | | | | | |
Collapse
|
12
|
Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Prétet JL. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol 2005; 35:270-7. [PMID: 16214397 DOI: 10.1016/j.jcv.2005.09.001] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2005] [Revised: 08/01/2005] [Accepted: 09/05/2005] [Indexed: 10/25/2022]
Abstract
BACKGROUND High burden of high risk human papillomavirus (HR HPV) has been shown to be predictive for the development of high grade cervical lesions and invasive cancers. However, low viral load cannot inevitably exclude progression towards cervical diseases. Moreover, few studies addressed whether viral load could predict infection clearance. OBJECTIVES We carried out a retrospective study to analyze the variations of HPV16 load over time as a predictive marker of clinical outcome. STUDY DESIGN The population consisted of 38 women who were found HR HPV positive by HCII test at study entry. Among them, 13 had developed a CIN2/3 (cases) and 25 had a negative HCII test and a normal cytology (controls) at study exit. The HPV16 DNA loads were quantified in 132 longitudinal cervical samples using quantitative real-time PCR. RESULTS At study entry, the median of HPV16 load was not statistically different between controls and cases. However, when using a cut-off value of 200 copies/10(3) cells, the rate of cumulative incidence of CIN2/3 at 18 months increased from 14% in women with a load<or=200 copies/10(3) cells to 48% in women with a load>200 copies/10(3) cells. The longitudinal analysis performed on follow-up samples showed that in cases the progression to CIN2/3 was linked to HPV16 burden increasing over time, whereas in controls a decrease of at least 1 log HPV16 DNA load was observed over>or=2 time points. CONCLUSIONS These results show that kinetics of HPV load, rather than a single HPV detection, might be more reliable to estimate whether a HPV infection will progress or be cleared.
Collapse
Affiliation(s)
- S Monnier-Benoit
- Laboratoire de Biologie Cellulaire et Moléculaire, EA 3181, IFR 133, Université de Franche-Comté, Centre Hospitalier Universitaire Jean Minjoz, Boulevard A Fleming, 25030 Besançon Cedex, France
| | | | | | | | | | | |
Collapse
|
13
|
Charlot JF, Prétet JL, Haughey C, Mougin C. Mitochondrial translocation of p53 and mitochondrial membrane potential (Delta Psi m) dissipation are early events in staurosporine-induced apoptosis of wild type and mutated p53 epithelial cells. Apoptosis 2005; 9:333-43. [PMID: 15258465 DOI: 10.1023/b:appt.0000025810.58981.4c] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The mitochondrial localization of p53 is an important event in p53-dependent apoptosis. Some p53 mutants defective for transcription also facilitate apoptosis through changes of the mitochondria. Here, apoptosis of HeLa and CaSki cells (p53(wt)), C33A and HaCat cells (p53(mt)) and SaOs-2 cells (p53 deficient) was induced by 300 nM staurosporine. We showed that wild-type p53, as well as p53 mutants, were transiently located to the mitochondria with changes in the mitochondrial membrane potential (Delta Psi m). However, in C33A cells harboring a p53 mutated on its DNA binding domain, Delta Psi m collapse and Sub-G1 DNA content were reduced compared to p53(wt) cells, whereas no significant difference was observed in HaCat cells with a p53 mutated on UV hot spots. In addition, inhibition of the mitochondrial permeability transition pores by cyclosporine A significantly reduced the Delta Psi m loss and the sub-G1 DNA content in p53 positive cells. These results indicate that Delta Psi m collapse is an early and necessary event, which plays an important role in apoptosis of immortal mammalian cells.
Collapse
Affiliation(s)
- J F Charlot
- EA 3181, Laboratoire de Biologie Cellulaire et Moléculaire (IBCT, IFR 133), CHU Jean Minjoz, 2 Boulevard Fleming, 25030 Besançon Cedex, France
| | | | | | | |
Collapse
|
14
|
Bard E, Riethmuller D, Meillet D, Prétet JL, Schaal JP, Mougin C, Seillès E. High-Risk Papillomavirus Infection Is Associated with Altered Antibody Responses in Genital Tract: Non-specific Responses in HPV Infection. Viral Immunol 2004; 17:381-9. [PMID: 15357904 DOI: 10.1089/vim.2004.17.381] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
In order to gain more information about local humoral immune responses to HPV infection, we quantified IgG, IgM, secretory-IgA (S-IgA), and total-IgA by ELISA, and lysozyme and lactoferrin by TR-IFMA, in cervical and cervicovaginal secretions of 40 healthy women and 28 high-risk HPV infected patients (11 were HPV16+). IgG, total-IgA, and S-IgA concentrations in cervicovaginal secretions (p < 0.0001) and high IgG and total-IgA concentrations (p < 0.001 and p < 0.01, respectively) in endocervical secretions were significantly higher in HPV+ patients than in the healthy group. Since the S-IgA/total-IgA ratio was significantly lower in cervicovaginal (7.5%) and endocervical secretions (36.5%) in HPV+ women compared to the control group (p < 0.003 and p < 0.001, respectively), HPV could be responsible for an increase in local production of non-secretory IgA (monomeric and dimeric forms). IgG and total-IgA concentrations in cervicovaginal and endocervical secretions fell in the same general percentage range in both HPV16+ and HPV+ groups (80% and 15%, respectively). However, the S-IgA/total-IgA ratio was much lower in HPV16+ than in HPV+ women, in both cervicovaginal secretions (3.4%) (p < 0.003) and in endocervical secretions (23.3%) (p < 0.001). Innate immunity proteins and local S-IgA response could not stop the spread of HPV infection in spite of high lysozyme and lactoferrin concentrations. HPV16+ disturbed the local humoral immune system, which could partly explain its low clearance.
Collapse
Affiliation(s)
- E Bard
- Institut d'Etude et de Transfert de Gènes (EA 3181), Faculté de Médecine Pharmacie, Besançon, 35030 Cedex France
| | | | | | | | | | | | | |
Collapse
|
15
|
Dalstein V, Riethmuller D, Sautière JL, Prétet JL, Kantelip B, Schaal JP, Mougin C. Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus. Eur J Cancer 2004; 40:1225-32. [PMID: 15110887 DOI: 10.1016/j.ejca.2004.01.021] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2003] [Revised: 01/15/2004] [Accepted: 01/19/2004] [Indexed: 11/26/2022]
Abstract
The aim was to determine the relevance of human papillomavirus (HPV) testing in identifying high-grade cervical intraepithelial neoplasia or worse (CIN2/3+) in a hospital population (n=3574) characterised by a high rate of cytological abnormalities and high-risk HPV infections. According to the results of the initial Papanicolaou and HPV test, women were directly referred for colposcopy/biopsy or recalled for a control visit. Sensitivity and specificity were corrected for verification bias. HPV-testing sensitivity was 94.3%, higher than that of cytological testing at any cut-off point (65.1%-86.8%), while specificity was greater for cytology than for HPV testing (99.3% or 91.8% versus 83.4%). The combination of both tests allowed 100% sensitivity and negative predictive value. We conclude that HPV testing is a relevant tool for the detection of cervical disease. The best way of combining cytology and HPV detection in screening programmes should be evaluated in large-scale studies.
Collapse
Affiliation(s)
- V Dalstein
- Laboratoire de Biologie Cellulaire et Moléculaire, CHU de Besançon, Hôpital Jean Minjoz, 25030 Besançon cedex, France
| | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
BACKGROUND HSV fulminant hepatitis is a rare pathology. Rapid hepatic failure, as a consequence of extended liver damage, has generally been attributed to necrosis. As apoptosis can constitute another way for hepatocytes to die, we decided to investigate whether programmed cell death took place during HSV fulminant hepatitis. METHODS Liver sections were obtained from two cases of fulminant herpetic hepatitis as well as from hepatitis B virus and Rickettsia-infected livers. Herpes simplex virus infection was confirmed using in situ hybridization. Apoptosis was assessed by histopathological examination, p53, activated-caspase 3 and Fas immunohistochemistry and TUNEL labeling. RESULTS We report that the number of cells expressing activated-caspase 3 was largely increased in fulminant herpes simplex virus hepatitis, when compared to livers chronically infected by hepatitis B virus or from a Rickettsial acute hepatitis. Apoptosis of hepatocytes was confirmed by a positive double-staining for activated-caspase 3 and hepatocytes. Finally, the apoptotic process has progressed beyond the step of nuclear DNA cleavage as demonstrated by TUNEL labeling. CONCLUSION These data as a whole show that apoptosis is responsible, at least partially, for liver damage during HSV fulminant hepatitis.
Collapse
Affiliation(s)
- J-L Prétet
- Centre Hospitalier Universitaire Jean Minjoz, Boulevard A. Fleming, 25030 Besançon Cedex, France.
| | | | | | | | | | | |
Collapse
|
17
|
Bard E, Riethmuller D, Biichlé S, Meillet D, Prétet JL, Mougin C, Seillès E. Validation of a high sensitive immunoenzymatic assay to establish the origin of immunoglobulins in female genital secretions. J Immunoassay Immunochem 2002; 23:145-62. [PMID: 12033640 DOI: 10.1081/ias-120003658] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Several studies were carried out to characterize the humoral immune response on mucosal genital surfaces. However, the results obtained so far were particularly conflicting due to the absence of validation methods. The aim of this study was to develop and validate a quantitative ELISA method, which is sensitive and reproducible, to measure immunoglobulin and secretory immunoglobulin concentrations in various biological fluids. This quantitative, sensitive (detection limit = 1 microg/L) and reproducible (coefficient of variation < 15%) method could be of interest to study the effects of viral infections on mucosal non-specific immune response in genital tract. To explore the humoral response, serum, saliva, vaginal secretions, and cervicovaginal secretions from 18 women, 20-45 years old, were evaluated for total-IgA, secretory IgA, IgM, and IgG. Albumin level was also evaluated by immuno-nephelometry. The secretion rates of immunoglobulins were measured by calculating their relative coefficients of excretion by reference to albumin. Despite large individual variations, median immunoglobulin levels were higher in the endocervical secretions than in the cervicovaginal secretions. When we compared the rates of immunoglobulins in genital fluids, IgG prevalence was higher (80%) in cervicovaginal and endocervical secretions than IgA prevalence (12%). In contrast, digestive mucosal secretions, such as saliva, contained mostly IgA (80%). In cervicovaginal and endocervical secretions, IgG and IgM originated mainly from serum, whereas a local synthesis provided total-IgA and secretory IgA. These results allowed us to raise a possible hypothesis for the origin of immunoglobulins in the genital tract. They illustrated the peculiar feature of the female reproductive tract and the difficulty for this tissue to contribute in the mucosal associated lymphoid tissue. The low secretory-IgA and total-IgA levels could explain the particular sensitivity of the vagina and the cervix to infections.
Collapse
Affiliation(s)
- E Bard
- Institut d'Etude et de Transfert de Gènes (EA 3181), Faculté de Médecine-Pharmacie, Besançon, France
| | | | | | | | | | | | | |
Collapse
|
18
|
Mougin C, Dalstein V, Prétet JL, Gay C, Schaal JP, Riethmuller D. [Epidemiology of cervical papillomavirus infections. Recent knowledge]. Presse Med 2001; 30:1017-23. [PMID: 11433694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
Abstract
GENERAL DATA: There is now considerable evidence that high risk human papillomaviruses (HPV), such as HPV 16, are closely associated with cancer of the cervix. HPVs that are primarily transmitted through sexual contact, are found in over 99% of the cases of invasive cervical cancer. Although most women can be infected during their sexual life, a small minority is at risk for developing cancer. The long latency period between primary infection and cancer emergence suggests that additional factors are involved in the process of tumor development: sexual behavior, immune status, genetic predispositions, nutritional status, tobacco use, socio-economical level. NATURAL HISTORY: HPVs infect epithelial cells of the transformation zone of the cervix. As with other sexually transmitted diseases, the incidence of HPV infection is highest among young women. However, this viral infection is more often than not transient, because most individuals develop an effective type-specific immune response. Approximately 1% of the population has genital warts and 4% of women have cervical precancerous lesions: low grade squamous intraepithelial lesion (LGSIL) or high grade SIL. These last lesions preferentially observed in women aged 35-40 yrs are at high risk of progression towards an invasive cancer. ONCOGENIC POTENTIAL OF HPV: Pre-malignant and malignant cells arise as a result of HPV DNA integration in the host cellular genome, and overexpression of the viral E6 and E7 oncogenes. Cells acquire a proliferative advantage by escaping growth control exerted by p53 and p 105Rb. Both cellular proteins are indeed inactivated respectively by E6 and E7 proteins. Aneuploidy and karyotypic abnormalities are also key events in the tumor progression. A PREVENTABLE DISEASE: Cervical cancer is more than ever a preventable disease. While waiting for clinically applicable vaccination programs, strategies to prevent cervical cancer include 1) improved screening covering the widest possible population and using HPV testing, 2) close management and follow-up of women with precancerous lesions.
Collapse
Affiliation(s)
- C Mougin
- Laboratoire de Virologie-Biologie Cellulaire, EA 2085, Faculté de Médecine, Place Saint-Jacques, F 25000 Besançon.
| | | | | | | | | | | |
Collapse
|
19
|
Bernard B, Fest T, Prétet JL, Mougin C. Staurosporine-induced apoptosis of HPV positive and negative human cervical cancer cells from different points in the cell cycle. Cell Death Differ 2001; 8:234-44. [PMID: 11319606 DOI: 10.1038/sj.cdd.4400796] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2000] [Revised: 09/07/2000] [Accepted: 10/18/2000] [Indexed: 01/14/2023] Open
Abstract
In the present study, we compare the sensitivity of CaSki and HeLa cells (HPV positive, wild-type p53) and C33A cells (HPV negative, mutated p53) to a protein kinase inhibitor, the staurosporine (ST). We show that ST can reversibly arrest the three cervical-derived cell lines, either in G1 or in G2/M. Beyond certain ST concentrations or/and over 24 h exposure, the cells underwent apoptosis. This process took place in G1 and G2/M for C33A and CaSki plus HeLa cell lines, respectively. By using an in vitro cell-free system, we demonstrated that cytoplasmic extracts from apoptotic cells were sufficient to induce hallmarks of programmed cell death on isolated nuclei. Moreover, we found that only G2/M cytoplasmic extracts from viable CaSki and HeLa cells supplemented with ST, triggered apoptosis while exclusively G1 cytoplasmic fractions from C33A cells were efficient. Our study describes a possible involvement of the HPV infection or/and p53 status in this different ST-induced apoptosis susceptibility.
Collapse
Affiliation(s)
- B Bernard
- Laboratoire de Biologie cellulaire et Virale, Faculté de Médecine et de Pharmacie, Place Saint-Jacques, Besançon Cedex, 25030, France
| | | | | | | |
Collapse
|
20
|
MESH Headings
- Amino Acid Sequence
- Animals
- Base Sequence
- Molecular Sequence Data
- Pan troglodytes/genetics
- Protein Structure, Secondary
- Receptors, CXCR6
- Receptors, Chemokine
- Receptors, Cytokine/chemistry
- Receptors, Cytokine/genetics
- Receptors, G-Protein-Coupled
- Receptors, Peptide/chemistry
- Receptors, Peptide/genetics
- Receptors, Virus/chemistry
- Receptors, Virus/genetics
- Reverse Transcriptase Polymerase Chain Reaction
Collapse
Affiliation(s)
- A Brussel
- Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, INSERM U445, Institut Cochin de Génétique Moléculaire, Université René Decartes, Paris, France
| | | | | | | |
Collapse
|
21
|
Affiliation(s)
- J L Prétet
- Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, INSERM U445, Institut Cochin de Génétique Moléculaire, Université René Descartes, Paris, France
| | | | | | | |
Collapse
|
22
|
Prétet JL, Guillet JG, Butor C. New widespread CXCR4 allele in rhesus macaques does not predict subspecies or clinical evolution. AIDS Res Hum Retroviruses 1998; 14:639-41. [PMID: 9591719 DOI: 10.1089/aid.1998.14.639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J L Prétet
- Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, INSERM U445, Institut Cochin de Génétique Moléculaire, Université René Descartes, Paris, France
| | | | | |
Collapse
|
23
|
Abstract
Chemokine receptors are molecules involved in the fusion of immunodeficiency viruses after their attachment. As chimpanzees are the animal model for infection by HIV-1, we cloned and sequenced chimpanzee CXCR4 and CCR5 from PBMCs. Chimpanzee CXCR4 was found to be identical to human CXCR4, which provides an explanation for the sensitivity of chimpanzees to lymphotropic isolates of HIV-1. Chimpanzee CCR5 showed two substitutions with respect to human CCR5. However, we show that the macrophage-tropic isolate HIV-1-Ba-L can use chimpanzee CCR5 as a fusion receptor. Therefore, the resistance of chimpanzee PBMCs to infection by macrophage-tropic isolates of HIV-1 is unlikely to be due to substitutions in CCR5.
Collapse
Affiliation(s)
- J L Prétet
- Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, INSERM U445, Institut Cochin de Génétique Moléculaire, Université René Descartes, Paris, France
| | | | | | | | | |
Collapse
|